FDC Ltd. (FDC) AI Stock Analysis

• Market Cap: ₹60.26B
• Dividend Yield: 1.22%
• Average Volume (3M): 16.03K
• Price to Earnings (P/E): 27.8
• Beta (1Y): 0.92
• Revenue Growth: 0.25%
• EPS Growth: -28.79%
• Country: IN
• Employees: 6,659
• Sector: Services
• Sector Strength: N/A
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.74
• Shares Outstanding: 162,810,090
• 10 Day Avg. Volume: 4,978
• 30 Day Avg. Volume: 16,030
• PEG Ratio: -2.10
• Price to Book (P/B): 2.86
• Price to Sales (P/S): 3.10
• P/FCF Ratio: 24.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: ₹430.00 ▲(4.85% Upside)
• Action: Reiterated Date: 11/11/25
• Date: Action: Reiterated 11/11/25

FDC Ltd.'s overall stock score is primarily influenced by its solid financial performance, which is offset by bearish technical indicators and a high valuation. The company's strong balance sheet and operational efficiency are positive factors, but the stock's current technical weakness and relatively high P/E ratio present challenges.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Balance Sheet Strength

A strong balance sheet with low leverage enhances financial stability and provides flexibility for future investments or downturns.

Cash Flow Generation

Robust cash flow generation supports operational needs and strategic investments, ensuring sustainable growth and shareholder returns.

Negative Factors

Profitability Pressure

Decreasing net profit margins suggest challenges in cost control or pricing power, potentially impacting long-term profitability.

Earnings Growth Decline

Negative EPS growth reflects challenges in maintaining earnings momentum, which could affect investor confidence and future valuations.

Profit Conversion

Inefficient profit conversion to cash flow can limit reinvestment capacity and affect liquidity, posing risks to long-term growth.

FDC Ltd. Business Overview & Revenue Model

Company Description

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others; and oral rehydration salts. It provides specialized formulations primarily under the Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm brand names. The company also offers anti-oxidants, balanced energy drinks, and vitamins and nutraceuticals under the Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl-LBW, Simyl-MCT, and Zefrich brands. In addition, it provides various active pharmaceutical ingredients. FDC Limited was founded in 1936 and is headquartered in Mumbai, India.

How the Company Makes Money

FDC generates revenue primarily through the sale of its pharmaceutical products, including prescription medications and over-the-counter drugs. The company's revenue model is based on direct sales to hospitals, pharmacies, and healthcare providers, as well as partnerships with distributors and retailers. Key revenue streams include product sales, licensing agreements for proprietary formulations, and collaborations with research institutions for developing new drugs. Additionally, FDC may benefit from government contracts and grants for public health initiatives, contributing to its overall earnings.

FDC Ltd. Financial Statement Overview

Summary

FDC Ltd. exhibits solid financial health with consistent revenue growth and strong balance sheet stability. While profitability metrics show some pressure, the company's operational efficiency and cash flow generation remain commendable. The low leverage and high equity ratio provide a cushion against potential risks.

Income Statement

FDC Ltd. has shown consistent revenue growth over the years, with a notable increase of 8.9% from 2024 to 2025. The gross profit margin has remained strong, reflecting efficient cost management. However, the net profit margin has slightly decreased, indicating some pressure on profitability. The EBIT and EBITDA margins are stable, showcasing operational efficiency.

Balance Sheet

The company's balance sheet is robust, with a low debt-to-equity ratio, indicating conservative leverage. The equity ratio is high, reflecting strong financial stability. Return on equity has decreased slightly, but remains healthy, suggesting effective use of shareholders' funds.

Cash Flow

FDC Ltd. has demonstrated strong free cash flow growth, with a significant increase from 2024 to 2025. The operating cash flow to net income ratio is favorable, indicating good cash generation relative to earnings. However, the free cash flow to net income ratio suggests room for improvement in converting profits into free cash flow.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	21.18B	21.08B	19.35B	17.84B	15.26B	13.27B
Gross Profit	11.28B	8.36B	6.51B	11.28B	9.78B	9.00B
EBITDA	4.16B	4.15B	4.40B	3.01B	3.30B	4.29B
Net Income	2.69B	2.67B	3.05B	1.94B	2.16B	3.01B
Balance Sheet
Total Assets	0.00	27.14B	24.68B	23.43B	22.70B	19.56B
Cash, Cash Equivalents and Short-Term Investments	5.37B	5.37B	4.75B	4.84B	5.39B	5.57B
Total Debt	0.00	211.68M	205.19M	283.20M	322.04M	146.56M
Total Liabilities	-22.81B	4.33B	3.71B	3.62B	3.14B	2.22B
Stockholders Equity	22.81B	22.81B	20.97B	19.82B	19.57B	17.34B
Cash Flow
Free Cash Flow	0.00	2.67B	1.27B	418.21M	291.08M	1.45B
Operating Cash Flow	0.00	3.64B	2.21B	1.55B	1.62B	2.07B
Investing Cash Flow	0.00	-2.47B	-170.83M	111.35M	-1.45B	-771.54M
Financing Cash Flow	0.00	-913.47M	-2.02B	-1.80B	-98.37M	-1.29B

FDC Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 410.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FDC, the sentiment is Negative. The current price of 410.1 is above the 20-day moving average (MA) of 375.33, above the 50-day MA of 387.06, and below the 200-day MA of 434.72, indicating a bearish trend. The MACD of -3.97 indicates Positive momentum. The RSI at 40.47 is Neutral, neither overbought nor oversold. The STOCH value of 33.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:FDC.

FDC Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GPPL	75 Outperform	₹84.46B	17.40	―	4.98%	7.10%	29.89%
TCI	70 Outperform	₹78.80B	17.65	―	0.94%	9.97%	16.28%
IONEXCHANG	60 Neutral	₹55.05B	24.47	―	0.40%	11.56%	-2.78%
FDC	58 Neutral	₹60.26B	27.81	―	1.22%	0.25%	-28.79%
PNCINFRA	57 Neutral	₹54.57B	6.83	―	0.23%	-30.54%	-35.13%
THOMASCOOK	57 Neutral	₹50.47B	20.42	―	0.32%	11.02%	-9.59%
Sector *	55 Neutral	$13.29B	17.42	10.03%	0.93%	7.13%	-12.93%

FDC Ltd. Corporate Events

FDC Gets USFDA ANDA Nod for Fluconazole Tablets

FDC Ltd. has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application covering Fluconazole Tablets USP in strengths of 50 mg, 100 mg, 150 mg and 200 mg. The clearance enables FDC to market a generic version of the antifungal medicine in the United States, strengthening its presence in the key U.S. generics market and potentially expanding its revenue opportunities in the anti-infective segment.